NCT01843374 2026-03-05
Tremelimumab
MedImmune LLC
Phase 2 Active not recruiting
Clinical Trials
26 trialsNCT05005429 2025-12-23
BIMES
Fundación GECP
Phase 2 Completed
NCT02611037 2025-12-18
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT03502746 2024-05-14
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT02899195 2023-07-05
PrE0505
PrECOG, LLC.
Phase 2 Completed
NCT00101283 2023-07-03
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00738582 2022-09-22
Amatuximab
Morphotek
Phase 2 Completed
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01085630 2021-08-18
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003508 2021-04-27
Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
Burzynski Research Institute
Phase 2 Terminated
NCT00859495 2020-08-25
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
Columbia University
Phase 2 Terminated
NCT01112293 2020-04-10
Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02357147 2020-03-17
ARTEMIS
Morphotek
Phase 2 Terminated
NCT03175172 2019-04-04
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
Phase 2 Terminated
NCT00365053 2018-06-07
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01160458 2018-04-10
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00243074 2018-01-23
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00165503 2016-09-09
Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00509041 2016-08-11
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01024946 2015-05-12
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00459862 2015-02-24
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00392444 2014-05-21
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
National Cancer Institute (NCI)
Phase 2 Completed